Arcadia Biosciences (RKDA) Non-Current Deffered Revenue (2014 - 2017)

Arcadia Biosciences has reported Non-Current Deffered Revenue for 4 years, with the latest figure at $2.0 million in Q4 2017.

• For the quarter ending Q4 2017, Non-Current Deffered Revenue fell 34.68% year-over-year to $2.0 million; the trailing twelve-month figure through Dec 2017 stood at $2.0 million (down 34.68% YoY), and the FY2017 full-year result was $2.0 million, down 34.68% from the prior year.
• Non-Current Deffered Revenue for Q4 2017 stood at $2.0 million, down from $2.8 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $3.6 million in Q4 2014, with the low at $2.0 million in Q4 2017.
• Historically, Non-Current Deffered Revenue has averaged $2.8 million across 4 years, with a median of $2.8 million in 2017.
• The largest YoY upside for Non-Current Deffered Revenue was 28.44% in 2017 against a maximum downside of 34.68% in 2017.
• Arcadia Biosciences' Non-Current Deffered Revenue stood at $3.6 million in 2014, then decreased by 27.48% to $2.6 million in 2015, then advanced by 18.32% to $3.1 million in 2016, then tumbled by 34.68% to $2.0 million in 2017.
• The last three Non-Current Deffered Revenue figures came in at $2.0 million (Q4 2017), $2.8 million (Q3 2017), and $2.9 million (Q2 2017), per Business Quant data.